Specifically, a total of 526 women with HER2-positive breast cancers received either AC#4-DH#4 (n = 129) or TCHP#6 (n = 397), while a total of 326 women with triple-negative breast cancers received either AC#4-D#4 (n = 271) or AD#6 (n = 55). The gene discussed is ERBB2; the disease is breast carcinoma.